Navigation Links
BioMarin to Present at the Credit Suisse Healthcare Conference
Date:11/3/2011

NOVATO, Calif., Nov. 3, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development at BioMarin, will present a company update at the Credit Suisse Healthcare Conference in Phoenix on Thursday, November 10, 2011 at 3:30 p.m. MST.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA; PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU; BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease; and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme®, Kuvan® and Firdapse™ are registered trademarks of BioMarin Pharmaceutical Inc.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin Announces Roll-Out of National PKU Registry
2. BioMarin to Present at the Citi Biotech Day
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
5. BioMarin Corrects Information Included in Bloomberg Article
6. BioMarin Announces Third Quarter 2008 Financial Results
7. BioMarin to Present at the Credit Suisse Healthcare Conference
8. BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer
9. BioMarin to Present at the Piper Jaffray Healthcare Conference
10. BioMarin to Host Fourth Quarter and Full Year 2008 Financial Results Conference Call and Webcast on Wednesday, February 18 at 5:00 p.m. ET (23:00 CET)
11. BioMarin Announces Fourth Quarter and Full Year 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... , ... Bactana Animal Health, a company developing natural products aimed at reducing ... the gut microbiota, today announced the closing of its first round of funding. ... Capital Management, LLC and a number of private investors. The company will use the ...
(Date:3/29/2017)... and NEWARK, Del. , ... a privately-held regenerative medicine company, and W. L. ... science company, today announced a collaborative research agreement whereby ... implantable cell therapy delivery device technologies that provide protection ... a decade, ViaCyte has been developing innovative stem cell-derived ...
(Date:3/29/2017)... 2017 /PRNewswire/ -  GeneNews Limited (TSX:GEN) ("GeneNews" or the ... new risk stratification test for breast cancer, via its ... ("IDL"). BreastSentry incorporates a blood-based biomarker test with a sophisticated ... developing breast cancer.   ... BreastSentry measures the fasting plasma levels of ...
(Date:3/29/2017)... March 29, 2017 The Global Microfluidic Chips ... is a specialized and comprehensive study on the existing state of ... , Europe and Asia-Pacific ... East and Africa . ... Browse 172 Tables and Figures, ...
Breaking Biology Technology:
(Date:3/20/2017)... 2017 At this year,s CeBIT Chancellor Dr. ... DERMALOG. The Chancellor came to the DERMALOG stand together with the Japanese ... CeBIT partner country. At the largest German biometrics company the two government ... and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
(Date:3/16/2017)... HANOVER, Germany , March 16, 2017 CeBIT 2017 - Against ... Continue Reading ... Used combined in one project, multi-biometric solutions ... ... Identification Systems) ...
(Date:3/9/2017)... , March 9, 2017 4Dx has ... World Lung Imaging Workshop at the University of Pennsylvania. ... invited to deliver the latest data to world leaders ... event brings together leaders at the forefront of the ... lung imaging. "The quality of the ...
Breaking Biology News(10 mins):